Toggle Nav

Angiogenesis

Angiogenesis is the growth of new blood vessels from the existing vasculature. This process is involved in development, wound healing, embryo formation and tumor growth. Activation of angiogenesis leads to the release of pro-angiogenic growth factors such as VEGF, PDGF, FGF and TGF, which bind their receptors on endothelial cells within pre-existing vessels. As a result, it induces signal transduction of various pathways such as PI3K/Akt, Erk1/2, Smad and Notch, causing endothelial cells proliferation and migration. Endothelial cells use matrix metalloproteases and integrins to digest extracellular matrix and migrate into new area, where they lengthen and form tubes, generating new blood vessel.

During tumor angiogenesis, cancer cells stimulate formation of new blood vessel for delivering oxygen and nutrients to a tumor. As the tumor grows, cells at the center of the mass become starved of oxygen, causing hypoxia. It stabilizes the expression of a transcription factor, HIF-1α (hypoxia inducible factor-1), which binds HIF-1β to upregulate the expression of several angiogenesis-promoting genes. Moreover, growth factor signaling also stimulates HIF-1 activity in order to maintain oxygen homeostasis for growing cells.

Items 1-10 of 61

Page
per page
  1. CNX-774
    Catalog No. :
    B1408
    BTK inhibitor, orally active, irreversible and selective
    CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.
  2. 2,4-DPD
    Catalog No. :
    C4887
    cell permeable, competitive inhibitor of HIF-PH
  3. JNJ-42041935
    Catalog No. :
    C4752
    Hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor
  4. Adaptaquin
    Catalog No. :
    C4377
    HIF-prolyl hydroxylase-2 (PHD2) inhibitor
  5. Octyl-α-ketoglutarate
    Catalog No. :
    C4321
    prolyl hydroxylases (PHD) activator
  6. ACP-196
    Catalog No. :
    B6185
    irreversible BTK inhibitor
  7. Daprodustat(GSK1278863)
    Catalog No. :
    B6106
    HIF-prolyl hydroxylase inhibitor
  8. SB273005
    Catalog No. :
    B6003
    αvβ3 antagonist
  9. ONO-4059
    Catalog No. :
    B5941
    Highly potent and selective oral Btk inhibitor
  10. LFM-A13
    Catalog No. :
    B5952
    BTK-specific tyrosine kinase inhibitor

Items 1-10 of 61

Page
per page